Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience

Kalyan Nadiminti, MD, Christopher Strouse, MD, Praveen Vikas, MD, Lindsay Dozeman, Allyson Schultz, Sarah L Mott, Jillna Claus, Umar Farooq, MD, Margarida Silverman, MD, Michael Tomasson, MD, Fenghuang Zhan, MD PhD, Yogesh Jethava, MBBS, MDFRCPath, MRCP, Guido J. Tricot, MD PhD

Blood (2018) 132 (Supplement 1): 2152.

https://doi.org/10.1182/blood-2018-99-113890

Published: 2018

Journal Articles

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)

Kalyan Nadiminti, MD, Christopher Strouse, MD, Praveen Vikas, MD, Lindsay Dozeman, Allyson Schultz, Gabrielle Berns, Jillna Claus, Sarah L Mott, Umar Farooq, MD, Margarida Silverman, MD, Michael Tomasson, MD, Fenghuang Zhan, MD PhD, Yogesh Jethava, MBBS, MD FRCPath, MRCP

Blood (2018) 132 (Supplement 1): 2153.

https://doi.org/10.1182/blood-2018-99-118443

Published: 2018

Journal Articles

Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI) Score Predicts Non-Relapse Mortality (NRM) and Overall Survival (OS) in Multiple Myeloma Patients Undergoing Intensive Preparative Regimen with Autologous Stem Cell Transplantation (ASCT) Followed By Maintenance Therapy Using Novel Agents

Kalyan Nadiminti, MD, Umar Farooq, MD, Lindsay Dozeman, Sarah Mott, MS, Guido J. Tricot, MD PhD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Margarida Silverman, MD

Blood (2017) 130 (Supplement 1): 3281.

https://doi.org/10.1182/blood.V130.Suppl_1.3281.3281

Published: 2017

Journal Articles

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy Is Safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective Phase II Trial (NCT01849783)

Kalyan Nadiminti, MD, Lindsay Dozeman, Annick Tricot, Allyson Schultz, Sheila Ouverson, Fenghuang Zhan, MD PhD, Margarida Silverman, MD, Guido J. Tricot, MD PhD, Yogesh Jethava, MBBS,MDFRCPath,MRCP

Blood (2017) 130 (Supplement 1): 4543.

https://doi.org/10.1182/blood.V130.Suppl_1.4543.4543

Published: 2017

Journal Articles

Clinical Investigation of Mitochondrial Biogenesis in Multiple Myeloma

Xin Zhan, Reinaldo Franqui-Machin, Kalyan Nadiminti, MD, Huojun Cao, Brad A. Amendt, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Ivana Frech, DSc, PhD MBA, Fenghuang Zhan, MD PhD, Guido J. Tricot, MD PhD

Blood (2017) 130 (Supplement 1): 1785.

https://doi.org/10.1182/blood.V130.Suppl_1.1785.1785

Published: 2017

Journal Articles

Bortezomib, Dexamethasone, Thalidomide and Melphalan (VDT-Mel) Preparative Regimen in Autologous Stem Cell Transplant (ASCT) Results in a Very High Stringent CR (sCR) Rate in Multiple Myeloma (MM)

Kalyan Nadiminti, MD, Kamal Kant Singh Abbi, MBBS, Annick Tricot, Allyson Schultz, Lindsay Dozeman, Sarah L Mott, MS, Fenghuang Zhan, MD PhD, Guido J Tricot, MD PhD

Blood (2015) 126 (23): 1971.

https://doi.org/10.1182/blood.V126.23.1971.1971

Published: 2015

Journal Articles

Salvage Tandem Autologous Stem Cell Transplant with Consolidation for Relapsed Multiple Myeloma

Kamal Kant Singh Abbi, MBBS, Sonya Behrends, Margarida Silverman, Umar Farooq, MD, Kalyan Nadiminti, MD, Guido J Tricot, MD PhD

Blood (2015) 126 (23): 5497.

https://doi.org/10.1182/blood.V126.23.5497.5497

Published: 2015

Journal Articles

Potential Pitfalls of Serum Free Light Chain Analysis to Assess Treatment Response for Multiple Myeloma

Kamal Kant Singh Abbi, MBBS, Guido J Tricot, MD PhD, Margarida Silverman, MD, Kalyan Nadiminti, MD, Matthew Krasowski

Blood (2015) 126 (23): 5308.

https://doi.org/10.1182/blood.V126.23.5308.5308

Published: 2015

NARROW

Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)

Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI) Score Predicts Non-Relapse Mortality (NRM) and Overall Survival (OS) in Multiple Myeloma Patients Undergoing Intensive Preparative Regimen with Autologous Stem Cell Transplantation (ASCT) Followed By Maintenance Therapy Using Novel Agents

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy Is Safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective Phase II Trial (NCT01849783)

Clinical Investigation of Mitochondrial Biogenesis in Multiple Myeloma

Bortezomib, Dexamethasone, Thalidomide and Melphalan (VDT-Mel) Preparative Regimen in Autologous Stem Cell Transplant (ASCT) Results in a Very High Stringent CR (sCR) Rate in Multiple Myeloma (MM)

Salvage Tandem Autologous Stem Cell Transplant with Consolidation for Relapsed Multiple Myeloma

Potential Pitfalls of Serum Free Light Chain Analysis to Assess Treatment Response for Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only